Antidiabetic	B:C0935929
potential	O
of	O
bioactive	O
molecules	O
coated	O
chitosan	B:C0162969
nanoparticles	I:C0162969
in	O
experimental	O
rats	B:C0034721
.	O

The	O
present	O
study	B:C2603343
was	O
carried	O
out	O
to	O
examine	O
the	O
antidiabetic	B:C0935929
effects	O
of	O
chitosan	B:C0162969
nanoparticles	I:C0162969
(	O
chitosan	B:C0162969
nanoparticles	I:C0162969
)	O
loaded	O
with	O
(	O
Stevia	B:C3267306
rebaudiana	I:C3267306
leaf	I:C3267306
extract	I:C3267306
-	O
SRLE	B:C3267306
)	O
bioactive	O
molecules	O
in	O
a	O
rat	B:C0034721
model	B:C0012644
of	O
streptozotocin	B:C0038432
(	O
streptozotocin	B:C0038432
)	O
induced	O
diabetes	B:C0011853
mellitus	I:C0011853
.	O

Successful	O
crosslinking	O
of	O
the	O
bioactive	O
molecules	O
to	O
the	O
chitosan	B:C0162969
nanoparticles	I:C0162969
was	O
confirmed	O
by	O
Fourier	B:C0206055
Transform	I:C0206055
Infrared	I:C0206055
Spectroscopy	I:C0206055
(	O
Fourier	B:C0206055
Transform	I:C0206055
Infrared	I:C0206055
Spectroscopy	I:C0206055
)	O
.	O

The	O
colloidal	O
characteristics	O
of	O
the	O
synthesized	O
nanoparticles	B:C0162969
were	O
revealed	O
by	O
X	O
-	O
ray	O
Diffraction	O
(	O
XRD	O
)	O
analysis	O
.	O

Morphological	B:C0543482
analysis	B:C0936012
by	O
Transmission	B:C0678118
Electron	I:C0678118
Microscopy	I:C0678118
(	O
Transmission	B:C0678118
Electron	I:C0678118
Microscopy	I:C0678118
)	O
revealed	O
that	O
the	O
bioactive	O
molecule	O
-	O
loaded	O
chitosan	B:C0162969
nanoparticles	I:C0162969
were	O
well	O
-	O
dispersed	O
and	O
spherical	B:C0332501
or	O
polygonal	B:C2347622
in	O
shape	B:C0332479
with	O
an	O
average	B:C0456389
size	I:C0456389
of	O
<	O
73.27nm	O
than	O
the	O
z	O
-average	O
value	O
(	O
327nm	O
)	O
as	O
measured	O
by	O
Dynamic	B:C1882368
Light	I:C1882368
Scattering	I:C1882368
(	O
Dynamic	B:C1882368
Light	I:C1882368
Scattering	I:C1882368
)	O
.	O

SRLE	B:C3267306
CNP	B:C0162969
-	O
treated	O
diabetic	B:C0011853
rats	B:C0034721
showed	O
a	O
significant	O
reduction	O
in	O
their	O
mean	O
fasting	B:C1261430
blood	I:C1261430
glucose	I:C1261430
level	I:C1261430
compared	O
with	O
the	O
diabetic	B:C0011853
control	O
group	O
.	O

The	O
serum	B:C0229671
levels	O
of	O
various	O
enzymes	B:C0014442
viz.	O
,	O
serum	B:C0242192
glutamic	I:C0242192
oxaloacetic	I:C0242192
transaminase	I:C0242192
(	O
serum	B:C0242192
glutamic	I:C0242192
oxaloacetic	I:C0242192
transaminase	I:C0242192
)	O
,	O
serum	B:C0376147
glutamic	I:C0376147
pyruvic	I:C0376147
transaminase	I:C0376147
(	O
serum	B:C0376147
glutamic	I:C0376147
pyruvic	I:C0376147
transaminase	I:C0376147
)	O
,	O
alkaline	B:C0002059
phosphatases	I:C0002059
(	O
alkaline	B:C0002059
phosphatases	I:C0002059
)	O
,	O
lipid	B:C0023775
peroxidation	I:C0023775
,	O
and	O
antioxidant	B:C0003402
such	O
as	O
catalase	B:C0007367
(	O
catalase	B:C0007367
)	O
,	O
reduced	B:C0034917
glutathione	I:C0034917
(	O
GSH	B:C0034917
)	O
,	O
and	O
superoxide	B:C0038838
dismutase	I:C0038838
(	O
superoxide	B:C0038838
dismutase	I:C0038838
)	O
in	O
the	O
SRLE	B:C3267306
CNP	B:C0162969
-	O
treated	O
group	O
were	O
closer	O
to	O
normal	O
levels	O
than	O
those	O
in	O
the	O
diabetic	B:C0011853
control	O
group	O
.	O

